A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.

Click here to get instant access to the guide

Johan Wedell-Wedellsborg net worth and biography

Johan Wedell-Wedellsborg Biography and Net Worth

Director of Y-mAbs Therapeutics

Johan Wedell-Wedellsborg is Owner and Chairman of the Board of Weco Group, which he took over in 2001. Weco Group is primarily a Ship Owning Company, which operates within the product tanker segment, multi-purpose vessels, RORO line and handy size bulk carriers. The shipping part of Weco Group records annual revenue of approximately $200 million. Besides shipping, Weco Group also is involved in realty investments, financial services, art and biotech. Wedell-Wedellsborg is educated within shipping in Hamburg, Germany and has also worked out of London in the United Kingdom and Houston, Texas.

What is Johan Wedell-Wedellsborg's net worth?: The estimated net worth of Johan Wedell-Wedellsborg is at least $65.14 million as of November 27th, 2023. Mr. Wedell-Wedellsborg owns 4,342,721 shares of Y-mAbs Therapeutics stock worth more than $65,140,815 as of April 18th. This net worth estimate does not reflect any other assets that Mr. Wedell-Wedellsborg may own. Learn More about Johan Wedell-Wedellsborg's net worth.
How do I contact Johan Wedell-Wedellsborg?: The corporate mailing address for Mr. Wedell-Wedellsborg and other Y-mAbs Therapeutics executives is 230 Park Avenue Suite 3350, NEW YORK NY, 10169. Y-mAbs Therapeutics can also be reached via phone at (646) 885-8505 and via email at [email protected]. Learn More on Johan Wedell-Wedellsborg's contact information.
Has Johan Wedell-Wedellsborg been buying or selling shares of Y-mAbs Therapeutics?: Johan Wedell-Wedellsborg has not been actively trading shares of Y-mAbs Therapeutics during the last quarter. Most recently, on Monday, November 27th, Johan Wedell-Wedellsborg bought 62,516 shares of Y-mAbs Therapeutics stock. The stock was acquired at an average cost of $5.49 per share, with a total value of $343,212.84. Following the completion of the transaction, the director now directly owns 4,342,721 shares of the company's stock, valued at $23,841,538.29. Learn More on Johan Wedell-Wedellsborg's trading history.
Who are Y-mAbs Therapeutics' active insiders?: Y-mAbs Therapeutics' insider roster includes Thomas Gad (Insider), Jorris Jan Wilms (Sr. VP & COO ), Bo Kruse (CFO), Vignesh Rajah (CMO), and Johan Wedell-Wedellsborg (Director). Learn More on Y-mAbs Therapeutics' active insiders.
Are insiders buying or selling shares of Y-mAbs Therapeutics?: During the last twelve months, Y-mAbs Therapeutics insiders bought shares 5 times. They purchased a total of 325,139 shares worth more than $2,395,729.86. During the last twelve months, insiders at the sold shares 4 times. They sold a total of 176,711 shares worth more than $1,085,282.83. The most recent insider tranaction occured on March, 5th when SVP Vignesh Rajah sold 1,711 shares worth more than $28,282.83. Insiders at Y-mAbs Therapeutics own 21.5% of the company. Learn More about insider trades at Y-mAbs Therapeutics.
Information on this page was last updated on 3/5/2024.

Johan Wedell-Wedellsborg Insider Trading History at Y-mAbs Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/27/2023	Buy	62,516	$5.49	$343,212.84	4,342,721
5/15/2023	Buy	101,740	$9.65	$981,791.00	4,280,205
6/3/2021	Sell	30,666	$33.19	$1,017,804.54	4,415,935
6/1/2021	Sell	6,864	$35.57	$244,152.48	4,453,465
5/28/2021	Sell	25,000	$36.34	$908,500.00	4,453,465
9/6/2019	Sell	17,243	$27.00	$465,561.00
8/30/2019	Sell	89,166	$26.58	$2,370,032.28
8/28/2019	Sell	49,357	$27.08	$1,336,587.56
8/21/2019	Sell	168,244	$27.57	$4,638,487.08

Johan Wedell-Wedellsborg Buying and Selling Activity at Y-mAbs Therapeutics

Y-mAbs Therapeutics Company Overview

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.

Today's Range

Now: $15.00

$14.82

$15.46

50 Day Range

MA: $15.69

$12.97

$18.69

2 Week Range

Now: $15.00

$4.60

$20.90

Volume

410,152 shs

Average Volume

402,223 shs

Market Capitalization

$656.70 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.74

[Urgent!] Generational Wealth Gameplan

From Crypto 101 Media | Ad